FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2194875245> ?p ?o ?g. }

• W2194875245 endingPage "e75" @default.
• W2194875245 startingPage "e64" @default.
• W2194875245 abstract "Concerns exist about the toxicity of drugs used in the implementation of large-scale antiretroviral programmes, and documentation of antiretroviral toxicity is essential. We did a systematic review and meta-analysis of adverse events among children and adolescents receiving regimens that contain abacavir, a widely used antiretroviral drug.We searched bibliographic databases and abstracts from relevant conferences from Jan 1, 2000, to March 1, 2015. All experimental and observational studies of HIV-infected patients aged 0-18 years who used abacavir, were eligible. Incidence of adverse outcomes in patients taking abacavir (number of new events in a period divided by population at risk at the beginning of the study) and relative risks (RR) compared with non-abacavir regimens were pooled with random effects models.Of 337 records and 21 conference abstracts identified, nine studies (eight full-text articles and one abstract) collected information about 2546 children, of whom 1769 (69%) were on abacavir regimens. Among children and adolescents taking abacavir, hypersensitivity reactions (eight studies) had a pooled incidence of 2·2% (95% CI 0·4-5·2); treatment switching or discontinuation (seven studies) pooled incidence was 10·9% (2·1-24·3); of grade 3-4 adverse events (six studies) pooled incidence was 9·9% (2·4-20·9); and adverse events other than hypersensitivity reaction (six studies) pooled incidence was 21·5% (2·8-48·4). Between-study inconsistency was significant for all outcomes (p<0·0001 for all inconsistencies). Incidence of death (four studies) was 3·3% (95% CI 1·5-5·6). In the three randomised clinical trials with comparative data, no increased risk of hypersensitivity reaction (pooled RR 1·08; 95% CI 0·19-6·15), grade 3 or 4 events (0·79 [0·44-1·42]), or death (1·72 [0·77-3·82]) was noted for abacavir relative to non-abacavir regimens. None of the reported deaths were related to abacavir.Abacavir-related toxicity occurs early after ART initiation and is manageable. Abacavir can be safely used for first-line or second-line antiretroviral regimens in children and adolescents, especially in sub-Saharan Africa were HLA B5701 genotype is rare.WHO." @default.
• W2194875245 created "2016-06-24" @default.
• W2194875245 creator A5002231420 @default.
• W2194875245 creator A5011349295 @default.
• W2194875245 creator A5030311798 @default.
• W2194875245 creator A5060251972 @default.
• W2194875245 creator A5065596403 @default.
• W2194875245 date "2016-02-01" @default.
• W2194875245 modified "2023-10-17" @default.
• W2194875245 title "Adverse events associated with abacavir use in HIV-infected children and adolescents: a systematic review and meta-analysis" @default.
• W2194875245 cites W1426208733 @default.
• W2194875245 cites W1517608807 @default.
• W2194875245 cites W1522247913 @default.
• W2194875245 cites W1563506370 @default.
• W2194875245 cites W1831705392 @default.
• W2194875245 cites W1966648617 @default.
• W2194875245 cites W1975735670 @default.
• W2194875245 cites W1984773683 @default.
• W2194875245 cites W1994210602 @default.
• W2194875245 cites W2014658051 @default.
• W2194875245 cites W2026977551 @default.
• W2194875245 cites W2033332204 @default.
• W2194875245 cites W2039509123 @default.
• W2194875245 cites W2041314794 @default.
• W2194875245 cites W2056285559 @default.
• W2194875245 cites W2066052937 @default.
• W2194875245 cites W2067059258 @default.
• W2194875245 cites W2080872787 @default.
• W2194875245 cites W2099214387 @default.
• W2194875245 cites W2112182958 @default.
• W2194875245 cites W2115086855 @default.
• W2194875245 cites W2135400982 @default.
• W2194875245 cites W2140019154 @default.
• W2194875245 cites W2167840994 @default.
• W2194875245 cites W4292229870 @default.
• W2194875245 doi "https://doi.org/10.1016/s2352-3018(15)00225-8" @default.
• W2194875245 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26847228" @default.
• W2194875245 hasPublicationYear "2016" @default.
• W2194875245 type Work @default.
• W2194875245 sameAs 2194875245 @default.
• W2194875245 citedByCount "19" @default.
• W2194875245 countsByYear W21948752452016 @default.
• W2194875245 countsByYear W21948752452017 @default.
• W2194875245 countsByYear W21948752452018 @default.
• W2194875245 countsByYear W21948752452019 @default.
• W2194875245 countsByYear W21948752452020 @default.
• W2194875245 countsByYear W21948752452021 @default.
• W2194875245 countsByYear W21948752452022 @default.
• W2194875245 crossrefType "journal-article" @default.
• W2194875245 hasAuthorship W2194875245A5002231420 @default.
• W2194875245 hasAuthorship W2194875245A5011349295 @default.
• W2194875245 hasAuthorship W2194875245A5030311798 @default.
• W2194875245 hasAuthorship W2194875245A5060251972 @default.
• W2194875245 hasAuthorship W2194875245A5065596403 @default.
• W2194875245 hasConcept C120665830 @default.
• W2194875245 hasConcept C121332964 @default.
• W2194875245 hasConcept C126322002 @default.
• W2194875245 hasConcept C142462285 @default.
• W2194875245 hasConcept C187212893 @default.
• W2194875245 hasConcept C197934379 @default.
• W2194875245 hasConcept C23131810 @default.
• W2194875245 hasConcept C2778715236 @default.
• W2194875245 hasConcept C2779465607 @default.
• W2194875245 hasConcept C2908647359 @default.
• W2194875245 hasConcept C2993143319 @default.
• W2194875245 hasConcept C3013748606 @default.
• W2194875245 hasConcept C44249647 @default.
• W2194875245 hasConcept C512399662 @default.
• W2194875245 hasConcept C61511704 @default.
• W2194875245 hasConcept C71924100 @default.
• W2194875245 hasConcept C82789193 @default.
• W2194875245 hasConcept C95190672 @default.
• W2194875245 hasConcept C99454951 @default.
• W2194875245 hasConceptScore W2194875245C120665830 @default.
• W2194875245 hasConceptScore W2194875245C121332964 @default.
• W2194875245 hasConceptScore W2194875245C126322002 @default.
• W2194875245 hasConceptScore W2194875245C142462285 @default.
• W2194875245 hasConceptScore W2194875245C187212893 @default.
• W2194875245 hasConceptScore W2194875245C197934379 @default.
• W2194875245 hasConceptScore W2194875245C23131810 @default.
• W2194875245 hasConceptScore W2194875245C2778715236 @default.
• W2194875245 hasConceptScore W2194875245C2779465607 @default.
• W2194875245 hasConceptScore W2194875245C2908647359 @default.
• W2194875245 hasConceptScore W2194875245C2993143319 @default.
• W2194875245 hasConceptScore W2194875245C3013748606 @default.
• W2194875245 hasConceptScore W2194875245C44249647 @default.
• W2194875245 hasConceptScore W2194875245C512399662 @default.
• W2194875245 hasConceptScore W2194875245C61511704 @default.
• W2194875245 hasConceptScore W2194875245C71924100 @default.
• W2194875245 hasConceptScore W2194875245C82789193 @default.
• W2194875245 hasConceptScore W2194875245C95190672 @default.
• W2194875245 hasConceptScore W2194875245C99454951 @default.
• W2194875245 hasIssue "2" @default.
• W2194875245 hasLocation W21948752451 @default.
• W2194875245 hasLocation W21948752452 @default.
• W2194875245 hasOpenAccess W2194875245 @default.
• W2194875245 hasPrimaryLocation W21948752451 @default.
• W2194875245 hasRelatedWork W136224194 @default.

• next